Researchers trained AI to read chemical changes in blood and estimate time of death with day level accuracy, even up to two ...

Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, today announced it has initiated a research collaboration with the University of ...

Structured Liquidity Ladder: The investment is funded in staged installments, allowing for up to eight payments, providing the company with consistent and predictable cash flows to support near-term ...

Executive SummaryThe global pharmaceutical drug delivery sector operates as a central pillar within the broader life sciences industry. As treatment protocols shift from conventional dosing toward ...

BOSTON, MA / ACCESS Newswire / February 23, 2026 / Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company ...

Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 ...

Operating capital runway sufficient into the fourth quarter of 2026 In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8 data submitted in late ...

Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases ...

Researchers have built a blood-based “clock” that estimates when Alzheimer’s symptoms will likely begin, potentially years before any memory loss appears. The model, validated in two major ...

Analysis from Moffitt Cancer Center has shown that DNA-derived protein epiScores measured in blood prior to treatment can ...

At-home diagnostic tests could cut wait times, easing pressure on Canada's health-care system and enhancing patient outcomes.

The Abu-Remaileh Lab published an atlas of proteins, found in lysosomes across different brain cell types, to advance research on neurodegenerative diseases.